Cite
Larotinib in patients with advanced and previously treated esophageal squamous cell carcinoma with epidermal growth factor receptor overexpression or amplification: an open-label, multicenter phase 1b study.
MLA
Liu, Rongrui, et al. “Larotinib in Patients with Advanced and Previously Treated Esophageal Squamous Cell Carcinoma with Epidermal Growth Factor Receptor Overexpression or Amplification: An Open-Label, Multicenter Phase 1b Study.” BMC Gastroenterology, vol. 21, no. 1, Oct. 2021, pp. 1–11. EBSCOhost, https://doi.org/10.1186/s12876-021-01982-4.
APA
Liu, R., Liu, L., Zhao, C., Bai, Y., Zheng, Y., Zhang, S., Li, N., Yang, J., Fan, Q., Wang, X., Zeng, S., Zhang, Y., Zhang, W., Zhuang, Y., Kang, N., Jiang, Y., Sun, H., & Xu, J. (2021). Larotinib in patients with advanced and previously treated esophageal squamous cell carcinoma with epidermal growth factor receptor overexpression or amplification: an open-label, multicenter phase 1b study. BMC Gastroenterology, 21(1), 1–11. https://doi.org/10.1186/s12876-021-01982-4
Chicago
Liu, Rongrui, Lianke Liu, Chuanhua Zhao, Yuxian Bai, Yulong Zheng, Shu Zhang, Ning Li, et al. 2021. “Larotinib in Patients with Advanced and Previously Treated Esophageal Squamous Cell Carcinoma with Epidermal Growth Factor Receptor Overexpression or Amplification: An Open-Label, Multicenter Phase 1b Study.” BMC Gastroenterology 21 (1): 1–11. doi:10.1186/s12876-021-01982-4.